Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

721 recalls, newest first

Class I · High risk

SILINTAN 25/pills

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

Ongoing Chemical / undeclared ANTHONY TRINH, 123Herbals LLC D-0388-2026
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026
Class II · Moderate risk

Prazosin Hydrochloride

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Ongoing Nitrosamine impurity Amerisource Health Services LLC NDC 60687-572-32 D-0103-2026
Class II · Moderate risk

Prazosin Hydrochloride

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Ongoing Nitrosamine impurity Amerisource Health Services LLC NDC 68084-997-01 D-0102-2026
Class II · Moderate risk

Prazosin Hydrochloride

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Ongoing Nitrosamine impurity Amerisource Health Services LLC NDC 68084-996-01 D-0101-2026

Recalls by year